The parent company of monosodium glutamate producer Ajinomoto (Malaysia) Bhd has launched a formal proposal to take the publicly-listed firm private, offering minority shareholders RM20 per share in an exercise valued at RM603.4 million. Ajinomoto Co Inc, which controls just over half the company with a 50.38% stake, presented the delisting plan to the board, setting in motion a transaction designed to wind up the firm's ten-year absence from capital market fundraising and unlock value for exiting investors.
The proposition arrives against a backdrop of chronically thin trading activity that has characterised the stock since its listing on the Main Market. Available data reveals that shares in Ajinomoto Malaysia have changed hands at an average daily volume of approximately 38,715 units over the past five years—a liquidity profile so subdued that minority investors have found it increasingly burdensome to liquidate their holdings at reasonable prices. This structural illiquidity underscores why the parent company views privatisation as a constructive path forward, offering shareholders a clear exit opportunity at a substantial premium rather than leaving them stranded in an effectively illiquid security.
The RM20-per-share offer represents material upside relative to recent market benchmarks. Measured against the five-day volume-weighted average price and the one-year equivalent, the bid price commands a premium of between 30.68% and 49.93%. Even more pointedly, it sits 31.58% above the share's closing price of RM15.20 recorded on June 19, 2026, the final trading day before suspension. For minority shareholders—who collectively control 49.62% of issued capital—the transaction thus delivers tangible compensation for accepting exit from a listing that has offered limited practical value as a trading vehicle.
Beyond immediate shareholder returns, Ajinomoto Co Inc's rationale for delisting hinges on operational and strategic flexibility. The company argued that maintaining listed status imposes substantial compliance burdens that absorb management bandwidth and corporate resources without corresponding benefit. Regulatory obligations such as continuous disclosure, periodic reporting, and periodic filings to Bursa Securities represent fixed costs of public ownership. By transitioning to private status, Ajinomoto Malaysia can streamline its corporate apparatus, eliminate these regulatory overheads, and redirect management attention toward core business development and operational improvement rather than administrative compliance.
The structure of the transaction itself reflects careful financial engineering. Ajinomoto Malaysia's current issued share capital stands at RM65.1 million, divided into 60.8 million shares. To fund the RM603.4 million repayment to entitled shareholders, the company will execute a bonus issue of 571.11 million shares financed through capitalisation of RM571.1 million in retained earnings. This mechanism allows the firm to bridge the gap between its modest existing capital base and the substantially larger aggregate payout required by the delisting formula. Following completion of the bonus issuance, all shares held by entitled shareholders—both their original holdings and the bonus allocation—will be cancelled entirely, leaving Ajinomoto Co Inc with 100% beneficial ownership.
The timing and scheduling of this transaction reflect careful coordination with the stock exchange and regulatory authorities. Trading in Ajinomoto Malaysia shares was suspended effective June 22, 2026, with resumption scheduled for the following business day on June 23. This sequencing permits announcement and initial market absorption before the suspension takes effect, allowing participants to digest the delisting announcement while the stock remains tradeable for a final period. The brief suspension window accommodates necessary administrative procedures and market microstructure adjustments required to process the delisting and capital actions.
From a Malaysian corporate finance perspective, this transaction exemplifies an increasingly common phenomenon among regional family offices and multinational parents: the strategic retreat from public markets by substantial controlling shareholders who view the burdens of listed status as outweighing the benefits. Ajinomoto Malaysia's extended abstention from equity capital-raising—more than a decade without a single fundraising exercise—represents the clearest possible signal that the public market had ceased to serve any economic purpose for the firm or its stakeholders. Under these circumstances, the decision to privatise emerges as commercially rational rather than defensive.
The delisting also carries implications for Bursa Malaysia's equity base and composition. The departure of Ajinomoto Malaysia, while not a marquee blue-chip exit, contributes to a broader trend of Asian-domiciled subsidiaries of Japanese multinationals reconsidering the strategic case for maintaining Southeast Asian public listings. As regulatory compliance costs escalate across the region and trading volumes in smaller-cap stocks remain structurally challenged, more foreign parents may evaluate similar privatisation strategies. This shift shapes the character and depth of regional capital markets in ways that extend beyond any single transaction.
For minority shareholders receiving the offer, acceptance represents pragmatic recognition of market realities. The RM20-per-share bid substantially exceeds recent trading values and provides cash certainty in place of illiquid equity exposure. While some investors might theoretically prefer to retain exposure to the underlying monosodium glutamate business in hopes of future operational improvements, the practical absence of trading liquidity renders such theoretical optionality economically meaningless. The majority of minority shareholders will likely view the privatisation as an opportune moment to realise holdings that they have struggled to sell at meaningful volumes in the open market.
The transaction must still navigate regulatory approval processes, including scrutiny from the Securities Commission Malaysia and formal shareholder voting. Bursa Malaysia will also require satisfaction of delisting conditions, which typically include confirmation that all regulatory requirements have been discharged and that shareholder approval has been secured. Given the controlling shareholder's substantial majority stake and the premium pricing of the offer, approval pathway appears relatively clear, though formal processes remain pending completion.
Looking forward, privatisation will grant Ajinomoto Malaysia substantially greater managerial discretion in operational and strategic matters. The parent company can pursue business objectives such as manufacturing process optimisation, supply chain restructuring, and capital allocation without the constraint of periodic public disclosure or the complexity of managing minority shareholder communications. While the company characterised this as "streamlining corporate structure," the practical effect extends to freedom from external scrutiny and stakeholder input—a shift that Japanese multinationals have increasingly sought across their Southeast Asian operations.
The RM603.4 million transaction valuation reflects realistic appraisal of the company's intrinsic worth and its strategic utility to the parent. For Ajinomoto Co Inc, consolidating complete ownership of a regional monosodium glutamate producer represents orderly closure of a public listing that had outlived its practical utility. For Malaysian minority shareholders, the RM20-per-share offer provides a concrete exit mechanism from an illiquid security, ending years of frustration in a market characterised by minimal daily trading. The transaction thus resolves tension between controlling and minority interests through a mechanism that delivers tangible value to both constituencies, albeit through fundamentally different paths.
